BioCentury
ARTICLE | Clinical News

ARRY-520: Phase II data

January 9, 2012 8:00 AM UTC

An open-label Phase II trial in 32 patients with relapsed or refractory MM showed that 1.5 mg/m 2 IV ARRY-520 produced 4 partial responses and 2 minimal responses. In a subgroup of 17 patients with MM refractory to both lenalidomide and bortezomib, ARRY-520 led to 2 partial responses and 1 minimal response. Median time to onset of response was 3.9 months. ARRY-520 was well tolerated with reversible, non-cumulative hematologic events reported as the most common adverse events. Patients received IV ARRY-520 on days 1 and 2 every 14 days plus prophylactic G-CSF support starting on day 3 or 4 for 5-7 days. Data were presented at the American Society of Hematology meeting in San Diego. ...